NTLA
Intellia Therapeutics, Inc.
A clinical-stage biotechnology company in Cambridge, Massachusetts, that uses CRISPR gene-editing technology to develop medicines for genetic diseases. Founded in 2014 with Nobel Prize-winning scientist Jennifer Doudna as a co-founder, it made history in 2021 by delivering the first-ever CRISPR edit inside a human body, targeting a protein that causes a rare heart condition. Its name blends "intelligence" with a biotech-style suffix.
CUSIP: 45826J105HealthcareUS3 holders
Total Value
$466.18M
Total Shares
30.28M
Net Share Change
+3.79M
Activity
3 buying
Investor
Value
Shares
Weight
Change
